<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05097209</url>
  </required_header>
  <id_info>
    <org_study_id>GLMU-07</org_study_id>
    <nct_id>NCT05097209</nct_id>
  </id_info>
  <brief_title>Camrelizumab Combined With Induction Chemotherapy and Intensity Modulated Radiotherapy for the Treatment of Locally Advanced Nasopharyngeal Carcinoma</brief_title>
  <official_title>Camrelizumab Combined With Induction Chemotherapy and Intensity Modulated Radiotherapy for the Treatment of Locally Advanced Nasopharyngeal Carcinoma:a Randomized, Multicenter, Phase 3 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wei Jiang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wuzhou Red Cross Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangxi Nanxishan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laibin people's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lingshan people's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guilin Medical University, China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial plans to enroll patients with stage III-IVA (AJCC 8th, included T1-2N2-3 and/or&#xD;
      T3-4N0-3 M0) locoregionally-advanced nasopharyngeal carcinoma (LANPC). Patients will be&#xD;
      randomized in a 1:1 ratio to receive 3 cycles of induction chemotherapy with gemcitabine and&#xD;
      cisplatin and concurrent cisplatin-radiation or 3 cycles of induction chemotherapy with&#xD;
      gemcitabine and cisplatin and radiation plus Camrelizumab. All patients will receive&#xD;
      intensity-modulated radiotherapy (IMRT). Camrelizumab will begin on day 1 of induction&#xD;
      chemotherapy every 3 weeks for 3 cycles and continue every 2 weeks for 9 cycles.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:To investigate the clinical efficacy of camrelizumab in the treatment of&#xD;
      locoregionally-advanced nasopharyngeal carcinoma (LANPC).&#xD;
&#xD;
      Outline:Patients with stage III-IVA (AJCC 8th, included T1-2N2-3 and/or T3-4N0-3 M0)&#xD;
      locoregionally-advanced nasopharyngeal carcinoma will be randomized in a 1:1 ratio to&#xD;
      experimental arm and active comparator arm. Patients in experimental arm will receive&#xD;
      induction chemotherapy with gemcitabine (1g/m2, d1 &amp; 8 of every cycle) and cisplatin&#xD;
      (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive&#xD;
      intensity-modulated radiotherapy (IMRT) of 6996cGy in 33 fractions will be given.&#xD;
      Camrelizumab 200mg will be given every 3 weeks for 3 cycles started on day 1 of induction&#xD;
      chemotherapy and every 2 weeks for 9 cycles thereafter. Patients in active comparator arm&#xD;
      will receive induction chemotherapy with gemcitabine (1g/m2, d1 &amp; 8 of every cycle) and&#xD;
      cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation.&#xD;
      Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy in 33 fractions will be given.&#xD;
      Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progress-free survival (PFS)</measure>
    <time_frame>3 years</time_frame>
    <description>Calculated from randomization to the date of progression or death from any cause, whichever occurred first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3 years</time_frame>
    <description>Calculated from randomization to the date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant Metastasis-free survival (DMFS)</measure>
    <time_frame>3 years</time_frame>
    <description>Calculated from randomization to the date of first distant metastasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional failure-free survival (LRRFS)</measure>
    <time_frame>3 years</time_frame>
    <description>Calculated from randomization to the date of locoregional relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>3 years</time_frame>
    <description>Graded according to CTCAE V5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of survival quality according to the EORTC Quality of Life Questionnaire (QLQ)-C30 (V3.0)</measure>
    <time_frame>1 year</time_frame>
    <description>Score of survival quality according to the EORTC Quality of Life Questionnaire (QLQ)-C30 (V3.0) before treatment, during treatment, after treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">458</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Camrelizumab arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 &amp; 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy in 33 fractions will be given. Camrelizumab 200mg will be given every 3 weeks for 3 cycles started on day 1 of induction chemotherapy and every 2 weeks for 9 cycles thereafter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemoradiation arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 &amp; 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy in 33 fractions will be given. Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>Camrelizumab 200mg will be given every 3 weeks for 3 cycles started on day 1 of induction chemotherapy and every 2 weeks for 9 cycles thereafter.</description>
    <arm_group_label>Camrelizumab arm</arm_group_label>
    <other_name>PD-1 antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine 1g/m2, d1 &amp; 8 of every cycle, every 3 weeks for 3 cycles before radiation</description>
    <arm_group_label>Camrelizumab arm</arm_group_label>
    <arm_group_label>Chemoradiation arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Induction Cisplatin</intervention_name>
    <description>Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation</description>
    <arm_group_label>Camrelizumab arm</arm_group_label>
    <arm_group_label>Chemoradiation arm</arm_group_label>
    <other_name>DDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity-modulated radiotherapy</intervention_name>
    <description>Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.</description>
    <arm_group_label>Camrelizumab arm</arm_group_label>
    <arm_group_label>Chemoradiation arm</arm_group_label>
    <other_name>IMRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Concurrent cisplatin</intervention_name>
    <description>Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation</description>
    <arm_group_label>Chemoradiation arm</arm_group_label>
    <other_name>DDP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with histologically confirmed nasopharyngeal carcinoma.&#xD;
&#xD;
          2. Tumor staged as III-IVA (AJCC 8th, included T1-2N2-3 and/or T3-4N0-3 M0).&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group performance status â‰¤1.&#xD;
&#xD;
          4. Adequate marrow function: neutrocyte countâ‰¥1.5Ã—10e9/L, hemoglobin â‰¥80g/L and platelet&#xD;
             count â‰¥80Ã—10e9/L.&#xD;
&#xD;
          5. Alanine Aminotransferase (ALT)/Aspartate Aminotransferase (AST) â‰¤2.5Ã—upper limit of&#xD;
             normal (ULN), and bilirubin â‰¤ 1.5Ã—ULN.&#xD;
&#xD;
          6. Adequate renal function: creatinine clearance rate â‰¥ 60 ml/min (Cockcroft-Gault&#xD;
             formula).&#xD;
&#xD;
          7. Patients must be informed of the investigational nature of this study and give written&#xD;
             informed consent.&#xD;
&#xD;
          8. Women of childbearing potential (WOCBP) who are sexually active must be willing to&#xD;
             adhere to effective contraception during treatment and for 1 year after the last dose&#xD;
             of study drug. Men who are sexually active with WOCBP must be willing to adhere to&#xD;
             effective contraception during treatment and for 1 year after the last dose of the&#xD;
             study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 70 or &lt; 18.&#xD;
&#xD;
          2. Hepatitis B surface antigen (HBsAg) positive and hepatitis B virus DNA &gt;1Ã—10e3&#xD;
             copies/ml or 200IU/ml&#xD;
&#xD;
          3. Hepatitis C virus (HCV) antibody positive&#xD;
&#xD;
          4. Has active autoimmune disease, except type I diabetes, hypothyroidism treated with&#xD;
             replacement therapy, and skin disease that doesn't require systemic treatment (e.g.,&#xD;
             vitiligo, psoriasis, or alopecia).&#xD;
&#xD;
          5. Has any condition that required systemic corticosteroid (equivalent to prednisone&#xD;
             &gt;10mg/d) or other immunosuppressive therapy within 28 days before informed consent.&#xD;
             Patients received systemic corticosteroid equivalent to prednisone â‰¤10mg/d, inhale or&#xD;
             topical corticosteroid will be allowed.&#xD;
&#xD;
          6. Has a known history of active TB (bacillus tuberculosis) within 1 year; patients with&#xD;
             adequately treated active TB over 1 year ago will be allowed.&#xD;
&#xD;
          7. Has a known history of interstitial lung disease.&#xD;
&#xD;
          8. Has received a live vaccine within 30 days before informed consent or will receive a&#xD;
             live vaccine in the near future.&#xD;
&#xD;
          9. Is pregnant or breastfeeding.&#xD;
&#xD;
         10. Prior malignancy within 5 years, except in situ cancer, adequately treated&#xD;
             non-melanoma skin cancer, and papillary thyroid carcinoma.&#xD;
&#xD;
         11. Has known allergy to large molecule protein products or any compound of camrelizumab.&#xD;
&#xD;
         12. Has a known history of human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
         13. Any other condition, including symptomatic heart failure, unstable angina, myocardial&#xD;
             infarction, active infection requiring systemic therapy, mental illness or&#xD;
             domestic/social factors, deemed by the investigator to be likely to interfere with a&#xD;
             patient's ability to sign informed consent, cooperate and participate in the study, or&#xD;
             interferes with the interpretation of the results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bin Zhang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wuzhou Red Cross Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yu-fei Pan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangxi Nanxishan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yi-xin Su, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lingshan people's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jian Zhang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laibin people's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei Jiang, Ph.D.</last_name>
    <phone>+86-773-2882906</phone>
    <email>weijiang@glmc.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangxi Nanxishan hospital</name>
      <address>
        <city>Guilin</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yufei Pan, M.D.</last_name>
      <phone>+8613737740520</phone>
      <email>23865934@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guilin Medical University</name>
      <address>
        <city>Guilin</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wei Jiang, Ph.D</last_name>
      <phone>+8613788561863</phone>
      <email>weijiang@glmc.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Laibin People's Hospital</name>
      <address>
        <city>Laibin</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jian Zhang, M.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linshan people's hospital</name>
      <address>
        <city>Linshan</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yi-xin Su</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuzhou Red Cross Hospital</name>
      <address>
        <city>Wuzhou</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Bin Zhang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 15, 2021</study_first_submitted>
  <study_first_submitted_qc>October 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Guilin Medical University, China</investigator_affiliation>
    <investigator_full_name>Wei Jiang</investigator_full_name>
    <investigator_title>Wei Jiang, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Nasopharyngeal carcinoma; Camrelizumab; Intensity Modulated Radiotherapy; PD-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

